We are live on
!
Find out more
ACM
ADAR1 Capital Management Portfolio holdings
AUM
$1.7B
1-Year Est. Return
340.85%
This Fund
S&P 500
This Quarter
Est. Return
+23.37%
1 Year Est. Return
+340.85%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$280M
AUM Growth
–
Cap. Flow
+$239M
Cap. Flow
% of AUM
85.54%
Top 10 Holdings %
Top 10 Hldgs %
59.33%
Holding
170
New
170
Increased
–
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Royalty Pharma
RPRX
|
+$36.3M |
| 2 |
Keros Therapeutics
KROS
|
+$21.6M |
| 3 |
Roivant Sciences
ROIV
|
+$12.2M |
| 4 |
MACK
Merrimack Pharmaceuticals, Inc.
MACK
|
+$6.94M |
| 5 |
Arbutus Biopharma
ABUS
|
+$6.79M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 68.64% |
| 2 | Technology | 1.12% |
| 3 | Financials | 1.12% |
| 4 | Materials | 0.99% |
| 5 | Consumer Staples | 0.5% |
Similar funds
RSCM
BCM
PP
GAM
FACM
II
RMC
OMC
ADAR1 Capital Management's Q4 2023 Portfolio in Review
Q4 2023 is the first quarter with a 13F filing on record for ADAR1 Capital Management, which disclosed 170 positions worth $280M. Its ten largest holdings account for 59% of the portfolio.
Its largest position is Royalty Pharma: 1,321,834 shares worth $37.1M.
By sector, the portfolio is most concentrated in Healthcare at 69% of assets, followed by Technology and Financials.
- ADAR1 Capital Management's largest Q4 2023 buy was Royalty Pharma: 1,321,834 shares worth $37.1M.
- ADAR1 Capital Management's ten largest holdings make up 59% of its $280M portfolio in Q4 2023.
- ADAR1 Capital Management disclosed 170 positions in Q4 2023, its first 13F filing on record.
Based on ADAR1 Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.